Clinical Trials

MorphoSys is committed to developing innovative antibody therapies with the potential to improve patients’ lives. The company is currently involved in clinical trials in cancer and inflammatory disorders, such as rheumatoid arthritis.

More information on the currently active clinical trials is available on the National Institutes of Health's clinical trials website, and the European Clinical Trials Register,

Please follow the links below for information on the enrollment criteria for each study and the participating countries:


MOR103 (anti-GM-CSF)

MOR103 is a fully human monoclonal antibody (mAb) directed towards human GM-CSF, a cytokine that leads to activation and proliferation of immune cells causing inflammation. Preclinical studies have shown that MOR103 neutralizes the biological function of human GM-CSF and significantly reduces inflammation by blocking its interaction with cell surface receptors of inflammatory cells, thus inhibiting their activation. These studies suggest that GM-CSF is involved in the pathogenesis of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.

The safety of MOR103 in patients with multiple sclerosis (MS) has recently been investigated in a phase Ib trial in Europe. Data of the study was presented in 2014.

For more information please click here:


MOR202 (anti-CD38)

MOR202 is a fully human monoclonal antibody (mAb) directed against CD38, which is one of the most strongly and uniformly expressed antigens on the surface of malignant plasma cells, and is an established diagnostic marker for multiple myeloma. Because of this expression pattern, an anti-CD38 antibody may have clinical utility as a new therapeutic approach to multiple myeloma treatment. Antibody-dependent cell-mediated cytotoxicity (ADCC) is the primary mode of action of MOR202.
MOR202 has demonstrated efficacy in preclinical models of multiple myeloma. MOR202 is currently being evaluated in a phase I/IIa clinical trial, which will investigate MOR202’s safety, tolerability and preliminary activity in patients with relapsed/refractory multiple myeloma.

For more information please click here:


MOR208 (anti-CD19)

MOR208 (formerly known as XmAb®5574) is a humanized monoclonal antibody directed against the antigen CD19 which is broadly expressed in B cell malignancies, such as non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL).
MOR208 has been engineered to possess significantly enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), thus improving a key mechanism of tumor cell killing and offering potential for enhanced efficacy compared to traditional antibodies for the treatment of cancer.
In preclinical lymphoma and leukemia models, MOR208 demonstrated strong anti-tumor potency, anti-proliferative and apoptotic activity. MOR208 has shown in a Phase 1/2a trial encouraging signs of preliminary anti-tumor activity and an acceptable safety and tolerability profile in patients with high-risk, heavily pretreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In 2013, MorphoSys has initiated Phase 2 clinical trials of MOR208 in B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin’s lymphoma (NHL).

For more information please click here:


Physicians interested in learning more about MorphoSys-sponsored clinical trials should contact:

Patients are kindly asked to contact their treating physicians, if they are interested in participating in any of MorphoSys clinical trials.


MorphoSys’s product candidates are investigational and are currently not approved for the treatment of any disease or condition anywhere in the world. They cannot be prescribed nor purchased for therapy at present.

The MorphoSys website may contain information on drug candidates and clinical trials sponsored by MorphoSys with the intention to increase the transparency of the Company’s clinical research.
Information contained within this website is not intended to replace the advice of a healthcare professional and should not be considered as a recommendation. Patients should always seek medical advice before making any decisions on their treatment.

All reasonable precautions have been taken to ensure the accuracy, security and confidentiality of information available through the site. MorphoSys may amend the information at any time without notice.


View Full Pipeline

MorphoSys’s portfolio comprises more than 90 antibody development programs.